Biondo Investment Advisors LLC decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 2.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 880 shares of the biopharmaceutical company’s stock after selling 25 shares during […]
Almanack Investment Partners LLC. acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 11,300 shares of the biopharmaceutical company’s stock, valued at approximately $8,153,000. Regeneron Pharmaceuticals comprises about 1.7% of Almanack […]
Desjardins Global Asset Management Inc. lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 23.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,749 shares of the biopharmaceutical company’s stock after selling 1,118 shares during the quarter. Desjardins […]
Peregrine Asset Advisers Inc. bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) during the 4th quarter, Holdings Channel reports. The fund bought 703 shares of the biopharmaceutical company’s stock, valued at approximately $507,000. Several other large investors have also recently made changes to their positions in the company. Massachusetts Financial Services […]
Bailard Inc. increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 2.3% in the 4th quarter, HoldingsChannel reports. The fund owned 9,070 shares of the biopharmaceutical company’s stock after purchasing an additional 207 shares during the period. Bailard Inc.’s holdings in Regeneron Pharmaceuticals were worth $6,544,000 as of its most recent filing […]